好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Switching from Injectable Therapy Leads to High Continuation Rate on Fingolimod
Multiple Sclerosis
(-)
221
Authors/Disclosures
Yves L. Lapierre, MD
PRESENTER
No disclosure on file
Daniel H. Selchen, MD (St.Michael'S Hospital) Dr. Selchen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Selchen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Selchen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Dr. Selchen has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Teva.
No disclosure on file
Virginia A. Devonshire, MD (UBC Hospital S126) Dr. Devonshire has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck- Serono. Dr. Devonshire has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Devonshire has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen . Dr. Devonshire has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for novartis. Dr. Devonshire has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for roche. Dr. Devonshire has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for biogen .
Robyn Schecter (Novartis) No disclosure on file